Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Olympus Medical Follows The Patient Pathway In New Strategic Plan

Value Creation Drive Is Underway Says CEO Takeuchi

Executive Summary

Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.

You may also be interested in...



Medtechs Drive To Keep The Status Quo In A Year Like No Other

The performances of the leading medtechs in the first year of the COVID-19 pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management skills and planning.

MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other

The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.

Olympus Targets A Bigger Medical Future

A medical company that has some other businesses – that is the shorthand description that Olympus Corp. of the Americas president and CEO Nacho Abia ascribes to a group that has emerged from difficult times with a new strategy, new structure and new determination. Targeted deals and M&A remain as important as ever to the group as it embarks, somewhat reinvented, on a new five-year plan.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel